CFN Insider explores how the U.S. cannabis industry is evolving and the potential impact of a DEA decision to reschedule the drug or its cannabinoid constituents with a leading market analyst and group of five legal experts. In addition, investment opportunities are identified that may arise from these changes.

In this episode, we take a look at some of the latest developments:

• FDA Approves GW Pharma's Epidolex
• Impact on rescheduling cannabis and DEA's rescheduling possibilities (isolate vs. cannabis plant)
• Resulting investment plays (cannabinoid drug developers, hemp extracts)
• Legalization Roundtable: State cannabis programs are flourishing (on both coasts) and fairing well under the Trump Administration on a macro level in light of the Cole Memo rescission, but federal restraints persist

Guests on the podcast include:

• Matt Karnes, Greenwave Advisors
• Rod Kight, Kight Law
• Seth Goldberg, Duane Morris LLP
• Silvia San Nichols, CEO of New Game Compliance
• Justin Hobson, Lane Powell